Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines

Journal: Bioorganic & Medicinal Chemistry, 2006, September 12; [E-publication ahead of print] Authors and Affiliation: Mahaney PE, Vu AT, McComas CC, Zhang P, Nogle LM, Watts WL, Sarkahian A, Leventhal L, Sullivan NR, Uveges AJ, Trybulski EJ; Chemical and Screening Sciences, Discovery Medicinal Chemistry, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA. PMID: 16973367 Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanamine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines.

1 Star2 Stars3 Stars4 Stars5 Stars (97 votes, average: 3.05 out of 5)

Leave a Reply